Clinical characterization of breakthrough bacteraemia: A survey of 392 episodes

Journal of Internal Medicine

Volumn 258, Issue 2, 2005, Pages 172-180

  López Dupla, Miguel ^a   Martinez, J A ^b   Vidal, F ^a   Almela, M ^b   Lopez J ^b   Marco, F ^b   Soriano, A ^b   Richart, C ^a   Mensa, J ^b  

^a HOSPITAL UNIVERSITARI JOAN XXIII   (Spain)

^b HOSPITAL CLÍNIC   (Spain)

Author keywords

Breakthrough bacteraemia; Coagulase negative staphylococci; Intravenous catheter; Nosocomial bacteraemia; P. aeruginosa; S. aureus

Indexed keywords

ANTIBIOTIC AGENT;

ADULT; AGED; ALLOGENIC BONE MARROW TRANSPLANTATION; ANTIBIOTIC THERAPY; BACTEREMIA; BLOOD CULTURE; CENTRAL VENOUS CATHETER; CLINICAL FEATURE; COAGULASE NEGATIVE STAPHYLOCOCCUS; CONTROLLED STUDY; ENDOCARDITIS; FEMALE; HEALTH SURVEY; HOSPITAL INFECTION; HUMAN; KIDNEY TRANSPLANTATION; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEUTROPENIA; PRIORITY JOURNAL; PROGNOSIS; PSEUDOMONAS AERUGINOSA; RETROSPECTIVE STUDY; REVIEW; SPAIN; STAPHYLOCOCCUS AUREUS;

ANTI-BACTERIAL AGENTS; BACTEREMIA; CATHETERIZATION, CENTRAL VENOUS; CROSS INFECTION; DRUG RESISTANCE, BACTERIAL; FEMALE; HUMANS; MALE; MIDDLE AGED; PSEUDOMONAS INFECTIONS; RETROSPECTIVE STUDIES; RISK FACTORS; SPAIN; STAPHYLOCOCCAL INFECTIONS;

EID: 22644447282     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2796.2005.01513.x     Document Type: Review

References (38)

1. Weinstein MP, Reller LB. Clinical importance of breakthrough bacteraemia. Am J Med 1984; 76: 175-80.
2. Spanik S, Trupl J, Kunova A et al. Risk factors, aetiology, therapy and outcome in 123 episodes of breakthrough bacteraemia and fungaemia during antimicrobial prophylaxis and therapy in cancer patients. J Med Microbiol 1997; 46: 517-23.
3. Anderson ET, Young LS, Hewitt WL. Simultaneous antibiotic levels in breakthrough gram-negative bacteremia. Am J Med 1976; 61: 493-7.
4. Wendt C, Messer SA, Hollis RJ, Pfaller MA, Wenzel RP, Herwaldt LA. Recurrent gram-negative bacteremia: incidence and clinical patterns. Clin Infect Dis 1999; 28: 611-7.
5. Nulens E, Bussels B, Bols A, Gordts B, Van Landuyt HW. Recurrent bacteremia by Chryseobacterium indologenes in an oncology patient with totally implanted intravascular device. Clin Microbiol Infect 2001; 7: 391-3.
6. Baran J, Riederer KM, Ramanathan J, Khatib R. Recurrent vancomycin-resistant Enterococcus bacteremia: prevalence, predisposing factors, and strain relatedness. Clin Infect Dis 2001; 32: 1381-3.
7. Mylotte JM, McDermont C. Recurrent gram-negative bacteremia. Am J Med 1988; 85: 159-63.
8. Noskin GA, Siddiqui F, Stosor V, Kruzynski J, Peterson LR. Successful treatment of persistent vancomycin-resistant Enterococcus faecium bacteremia with linezolid and gentamicin. Clin Infect Dis 1999; 28: 689-90.
9. Van Kerkhoven D, Peetermans WE, Verbist L, Verhaegen J. Breakthrough pneumococcal bacteremia in patients treated with claritromycin or oral beta-lactams. J Antimicrob Chemother 2003; 51: 691-6.
10. Spanik S, Trupl J, Studena M, Krcmery V Jr. Breakthrough nosocomial bacteraemia due to teicoplanin-resistant Staphylococcus haemolyticus in five patients with acute leukaemia. J Hosp Infect 1997; 35: 155-9.
11. Lonks JR, Garau J, Madeiros AA. Implications of antimicrobial resistance in the empirical treatment of community-acquired respiratory tract infections: the case of macrolides. J Antimicrob Chemother 2002; 50 (Suppl. S2): 87-92.
12. Van der Auwera P, Gerain J. Use of the quinolones in the prophylaxis and treatment of granulocytopenic immunocompromised cancer patients. Drugs 1993; 45 (Suppl. 3): 81-90.
13. Sperber SJ, Levine JF, Gross PA. Persistent MRSA bacteremia in a patient with low linezolid levels. Clin Infect Dis 2003; 36: 675-6.
14. Fortun J, Perez-Molina JA, Anon MT, Martinez-Beltran J, Loza E, Guerrero A. Right-sided endocarditis caused by Staphylococcus aureus in drug abusers. Antimicrob Agents Chemother 1995; 39: 525-8.
15. Kelley MA, Weber DJ, Gilligan P, Cohen MS. Breakthrough pneumococcal bacteremia in patients being treated with azithromycin and clarithromycin. Clin Infect Dis 2000; 31: 1008-11.
16. Lisby G, Brasholt MS, Teglbjerg L. Bacteremia and meningitis caused by a macrolide-sensitive strain of Streptococcus pneumoniae during treatment with azithromycin. Clin Infect Dis 2001; 33: 415-6.
17. Patrick CC, Kaplan SL, Backer CJ, Parisi JT, Mason EO. Persistent bacteremia due to coagulase-negative Staphylococci in low birth weight neonates. Pediatrics 1989; 84: 977-85.
18. Chapman RL, Faix RG. Persistent bacteremia and outcome in late onset infection among infants in a neonatal intensive care unit. Pediatr Infect Dis J 2003; 22: 17-21.
19. Vidal F, Mensa J, Almela M et al. Bacteremia in adults due to glucose non-fermentative gram-negative bacilli other than P. aeruginosa. Q J Med 2003; 96: 227-34.
20. National Committee for Clinical, Laboratory Standards. Standard Methods for the Dilution Antimicrobial Susceptibility Tests for Bacteria that Grow Aerobically, 2nd edn. Villanova, PA: National Committee for Clinical and Laboratory Standards, 1990. Approved Standard M7-A2.
21. Blot F, Nitenberg G, Brun-Buisson C. New tools in diagnosing catheter-related infections. Support Care Cancer 2000; 8: 287-92.
22. Raad I, Hanna HA, Alakech B, Chazinikolaou I, Johnson MM, Tarrand J. Differential time to positivity: a useful method for diagnosing catheter-related bloodstream infections. Ann Intern Med 2004; 140: 18-25.
23. National Nosocomial Infections Study. Site Definitions Manual. Atlanta, GA: Centers for Disease Control, 1972.
24. McCabe WR, Jackson GG. Gram negative bacteremia. I. Etiology and ecology. Arch Intern Med 1962; 110: 847-55.
25. Vidal F, Mensa J, Almela M et al. Epidemiology and outcome of Pseudomonas aeruginosa bacteremia, with special emphasis on the influence of antibiotic treatment. Analysis of 189 episodes. Arch Intern Med 1996; 156: 2121-6.
26. Chowers MY, Gottesman B, Paul M, Weinberger M, Pitlik S, Leibovici L. Persistent bacteremia in the absence of defined intravascular foci: clinical significance and risk factors. Eur J Clin Microb Infect Dis 2003; 22: 592-6.
27. Ninin E, Milpied N, Moreau P et al. Longitudinal study of bacterial, viral, and fungal infections in adult recipients of bone marrow transplants. Clin Infect Dis 2001; 33: 41-7.
28. Kirk JL, Greenfield RA, Slease RB, Epstein RB. Analysis of early infectious complications after autologous bone marrow transplantation. Cancer 1988; 62: 2445-50.
29. Reich G, Mapara MY, Reichardt P, Dörken B, Maschmeyer G. Infectious complications after high dose chemotherapy and autologous stem cell transplantation: comparison between patients with lymphoma or multiple myeloma and patients with solid tumours. Bone Marrow Transplant 2001; 27: 525-9.
30. Meyers JD. Infection in bone marrow transplant recipients. Am J Med 1986; 81: 27-38.
31. Nosanchuk JD, Sepkowitz KA, Pearse RN, White MH, Nimer SD, Armstrong D. Infectious complications of autologous bone marrow and peripheral stem cell transplantation for refractory leukaemia and lymphoma. Bone Marrow Transplant 1996; 18: 355-9.
32. Reymann MT, Holley HP Jr, Cobbs CG. Persistent bacteremia in staphylococcal endocarditis. Am J Med 1978; 65: 729-37.
33. Bouza E, Burillo A, Muñoz P. Catheter-related infections: diagnosis and intravascular treatment. Clin Microbiol Infect 2002; 8: 265-74.
34. Pascual A. Pathogenesis of catheter-related infections: lessons for new designs. Clin Microbiol Infect 2002; 8: 256-64.
35. Martinez-Martinez L, Pascual A, Perea EJ. Kinetics of adherence of mucoid and non-mucoid Pseudomonas aeruginosa to plastic catheters. J Med Microbiol 1991; 34: 7-12.
36. Cirera I, Bauer TM, Navasa M et al. Bacterial translocation of enteric organisms in patients with cirrhosis. J Hepatol 2001; 34: 150-5.
37. Young LS, Martin WJ, Meyer RD, Weinstein RJ, Anderson ET. Gram-negative bacteremia: microbiologic, immunologic and therapeutic considerations. Ann Intern Med 1977; 86: 456-71.
38. Bow EJ, Mandell LA, Louie TJ et al. Quinolone-based antibacterial chemoprophylaxis in neutropenic patients: effect of augmented gram-positive activity on infectious morbidity. National Cancer Institute of Canada Clinical Trials Group. Ann Intern Med 1996; 125: 183-90.